Genentech Licenses Sangamo’s DNA-Binding Technology For Protein Production
This article was originally published in The Pink Sheet Daily
Executive Summary
Genentech and Medarex are the only two firms with commercial licenses for the zinc finger DNA-binding protein technology.
You may also be interested in...
Sangamo Acquisition Of Edwards’ R&D Program Will Enhance Partnering Opportunities
Sangamo will acquire Edwards’ angiogenesis program based on zinc finger protein activation of the VEGF gene.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.